Targeted apoptosis of senescent cells restores health in progeroid mice

Cell·2017·Baar MP, Brandt RMC, Putavet DA, et al.·Cell

This study introduced FOXO4-DRI, a peptide designed to selectively eliminate senescent cells by disrupting the FOXO4-p53 interaction. In aged and progeroid mice, treatment restored fur density, kidney function, and physical activity, providing a proof of concept for peptide-based senolytic approaches.

Why this research is interesting

This is a foundational study for senolytic peptides. It demonstrates that a peptide can selectively target senescent cells, a concept with significant implications for aging research. It is frequently cited in longevity peptide discussions.

What the research says

FOXO4-DRI was designed to displace p53 from FOXO4 in senescent cells, triggering apoptosis. In progeroid (accelerated-aging) mice, treatment reversed several markers of aging including fur loss, reduced kidney function, and decreased physical activity.

What the evidence shows

This is animal research in mice, including both naturally aged and genetically modified progeroid models. No human clinical trials of FOXO4-DRI have been published.

What remains uncertain

Whether senolytic effects in mice translate to humans is unknown. Safety in humans, appropriate dosing, long-term effects, and whether the benefits extend to normally aged (not progeroid) animals all require further investigation.